---
document_datetime: 2026-01-16 10:50:46
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/rivastigmine-hexal-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: rivastigmine-hexal-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.7099177
conversion_datetime: 2026-01-17 13:18:35.747086
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.68.0
  docling-core: 2.59.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Rivastigmine HEXAL

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | This was an application for a variation | 15/01/2026                          |                                             | SmPC, Annex                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000301284                     | following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a - to update section 4 of the Package Leaflet following the same changes adopted for the reference product Exelon with procedure EMA/N/0000263584 Notification. The MAH took also the opportunity to make changes in section 4.2, 4.3 4.8 and 5.2 of the SmPC always based on reference product Exelon. In addition, minor updates were performed in throughout the SmPC, Annex II and PL as per QRD (Version 10.4,   |            |     | II and PL   |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|
| Variation type IA / EMA/VR/0000314603 | This was an application for a group of variations. B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.a Tightening of specification limits - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 28/11/2025 | N/A |             |

<div style=\"page-break-after: always\"></div>

|                                          | B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.a Tightening of specification limits - Accepted                    |            |                 |
|------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----------------|
| Article 61(3) / EMA/N/0000314324         | - Notification acc. Article 61(3) - Accepted Update of package leaflet with revised contact details of local representatives.                                       | 27/11/2025 | PL              |
| Variation type IA_IN / EMA/VR/0000244604 | B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.1 Not including batch control/testing - Accepted | 15/01/2025 | Annex II and PL |